Endocrine Abstracts

Introduction: Whether F18-choline PET/CT (FCH PET/CT) should replace Tc99m-sestaMIBI SPECT/CT (MIBI SPECT/CT) as a first-line imaging technique for preoperative localisation of parathyroid adenomas in primary hyperparathyroidism (pHPT) is unclear.Methods: We conducted a multicentre randomized open diagnostic intervention phase III trial in adults with primary hyperparathyroidism and indication for surgical treatment. Patients were assigned in a 1:1 ratio...

X-linked hypophosphatemia (XLH) is a rare genetic disease due to inactivation of the PHEX gene, which results in enhanced secretion of the phosphaturic hormone fibroblast growth factor 23 (FGF23); the latter induces renal phosphate wasting and hypophosphatemia. Skeletal and dental anomalies and recently described increase in cardiovascular risk are typical clinical findings. We retrospectively evaluated 58 adult patients with XLH from 9 Italian tertiary centres [34 females, 24...

Autosomal dominant hypocalcemia type 1 (ADH1) is a genetic disorder characterized by low serum calcium and low or inappropriately normal levels of PTH. It is caused by a heterozygous activating mutation of the calcium-sensing receptor (CASR) gene, resulting in decreased sensitivity of the receptor to low serum calcium. The aim of our study was to describe a series of patients with ADH1 followed at our outpatient clinic from 2011 to 2023. A total of 7 patients (4 femal...

Introduction: The HypoparaNet database includes 509 patients (110 men and 399 women) with chronic hypoparathyroidism (cHP), recruited and followed in 20 clinical centers in Italy from 2014 onwards. cHP etiology included 363 post-surgical cases (71.3%), 78 idiopathic cases (15.3%), and 64 patients with a genetic background (12.6%). Bone health is an important clinical aspect to be considered in patients with cHP, whose skeleton is exposed both to the cHP-induced alteration of b...

Management of skeletal fragility in women with early breast cancer (BC) under hormone-deprivation therapies (HDTs) may be a challenge and it is still unknown whether anti-osteoporotic therapies could be active in preventing fractures in pre-menopausal women exposed to HDTs. In this real-world, multicenter study, we evaluated the effectiveness of bone-active drmgs and determinants of vertebral fractures (VFs) in 306 pre-menopausal women (mean age 47.15±5.09, range: 30-54) wi...